List of Excipients in Branded Drug MIRABEGRON

Generic Drugs Containing MIRABEGRON

Company	Ingredient	NDC	Excipient
Qilu Pharmaceutical Co Ltd	mirabegron	67184-0571	BUTYLATED HYDROXYTOLUENE
Qilu Pharmaceutical Co Ltd	mirabegron	67184-0571	FERRIC OXIDE RED
Qilu Pharmaceutical Co Ltd	mirabegron	67184-0571	FERRIC OXIDE YELLOW
Qilu Pharmaceutical Co Ltd	mirabegron	67184-0571	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in MIRABEGRON?

# Of NDCs	Excipient
1	ACESULFAME POTASSIUM
6	BUTYLATED HYDROXYTOLUENE
5	CELLULOSE, MICROCRYSTALLINE
2	D&C YELLOW NO. 10 ALUMINUM LAKE

Mirabegron Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Mirabegron is a high-value extended-release beta-3 adrenergic agonist with two commercial formulation platforms: once-daily prolonged-release tablets and pediatric granules for oral suspension. The main excipient opportunity is not simple substitution. It is development of bioequivalent hydrophilic-matrix systems, pediatric taste-masked suspensions, low-risk reformulations, and manufacturing platforms that reduce tablet size, improve robustness, or support differentiated regulatory filings.

The commercial opportunity is supported by mirabegron’s low aqueous solubility, extended-release requirement, chronic use in overactive bladder, pediatric neurogenic detrusor overactivity, and substantial branded revenue exposure. Astellas markets mirabegron as Myrbetriq in the United States and Betmiga in several international markets. The principal competitive risks are generic extended-release tablets, vibegron, antimuscarinic drugs, and combination products.

What is the current mirabegron formulation and excipient profile?

Myrbetriq is supplied as 25 mg and 50 mg extended-release tablets. The product uses a hydrophilic controlled-release matrix rather than an immediate-release tablet. The FDA label identifies excipients including polyethylene oxide, hypromellose, macrogol, hydroxypropyl cellulose, magnesium stearate, butylated hydroxytoluene, and colorants, with composition varying by dosage strength and tablet coating.[1]

The formulation strategy has four functional layers:

Formulation function	Likely or disclosed excipient role	Commercial significance
Matrix formation	Polyethylene oxide and hypromellose	Controls water penetration and drug release
Granulation and binding	Hydroxypropyl cellulose	Supports tablet strength and content uniformity
Lubrication	Magnesium stearate	Supports compression and ejection
Plasticization and coating	Macrogol and hypromellose	Controls film properties and appearance
Oxidation control	Butylated hydroxytoluene	Protects formulation stability
Identification	Iron oxides and other colorants	Differentiates 25 mg and 50 mg strengths

Mirabegron is generally treated as a poorly water-soluble, permeability-sufficient compound. That profile creates formulation sensitivity around particle size, wetting, matrix hydration, polymer grade, compression force, and dissolution conditions. The active pharmaceutical ingredient is not well suited to a conventional immediate-release tablet for the branded once-daily indication.

What excipients are most important for mirabegron extended-release tablets?

The highest-value excipient is the release-controlling polymer. Polyethylene oxide and hypromellose can create a hydrated gel layer around the tablet. Drug release then depends on polymer swelling, erosion, diffusion, drug loading, tablet dimensions, and dissolution media.

Polyethylene oxide matrix

Polyethylene oxide is commercially attractive because it can produce prolonged release at relatively modest use levels and is compatible with direct compression or dry-granulation processes. Its risks include sensitivity to molecular weight, shear history, moisture, and oxidative degradation. High-molecular-weight grades can increase tablet size and processing demands.

A generic developer should screen:

• Molecular-weight grade and substitution level
• Polymer concentration
• Polymer-to-drug ratio
• Particle-size distribution
• Compression dwell time and hardness
• Release behavior after storage under humidity
• Alcohol dose-dumping performance
• Tablet integrity after coating and packaging

Polyethylene oxide also creates an opportunity for suppliers of high-purity, low-peroxide grades. A supplier that can demonstrate consistent molecular weight, low residual peroxide, narrow particle-size distribution, and reliable compaction performance can compete on more than price.

Hypromellose matrix

Hypromellose is a mature controlled-release excipient with strong regulatory familiarity. It provides formulation flexibility across hydrophilic matrix systems and can be used with polyethylene oxide or as an alternative matrix polymer.

A hypromellose-led formulation may offer:

• Easier global excipient acceptance
• Broader supplier availability
• Better supply-chain resilience
• Reduced dependence on a single polymer platform
• More predictable scale-up for conventional wet or dry granulation

The tradeoff is that replacing polyethylene oxide with hypromellose can alter release kinetics, tablet swelling, dissolution profiles, and food-effect behavior. A formulation cannot be treated as equivalent merely because both systems use hydrophilic polymers.

Wetting and solubilization strategy

Mirabegron’s solubility profile creates an opportunity for excipients that improve wetting without converting the product into an immediate-release formulation. Candidate technologies include surfactants, polymeric solubilizers, amorphous dispersions, micronized API, and co-processed excipients.

The commercial risk is overengineering. A surfactant or amorphous system may improve dissolution but can also change supersaturation, precipitation, food sensitivity, and in vivo exposure. For a generic extended-release product, the development target is a reproducible in vitro-in vivo relationship, not the fastest possible dissolution.

What excipient opportunities exist in pediatric mirabegron granules?

The pediatric platform is the most differentiated excipient opportunity. FDA approved Myrbetriq Granules for extended-release oral suspension for children aged 3 years and older with neurogenic detrusor overactivity associated with neurologic conditions.[2]

The granules must address requirements that do not apply to adult tablets:

• Dose flexibility by body weight
• Administration through a calibrated oral syringe
• Dispersion in water before dosing
• Acceptable taste and mouthfeel
• Physical stability after reconstitution
• Uniform drug distribution during withdrawal
• Resistance to sedimentation or rapid settling
• Compatibility with pediatric dosing devices
• Stability over the labeled in-use period

Potential excipient platforms include mannitol or other bulking agents, suspending polymers, wetting agents, surfactants, anti-caking agents, buffers, sweeteners, and flavor systems. The exact composition and quantitative formula of the reference product should be treated as protected product information unless disclosed in a regulatory document or patent.

Pediatric taste masking

Taste masking is a direct commercial opportunity because mirabegron is administered chronically and pediatric adherence is sensitive to bitterness, grittiness, and dosing complexity.

Available approaches include:

1. Polymer coating of drug particles
2. Ion-exchange or complexation systems
3. Lipid-based barriers
4. pH-dependent coating
5. Flavor and sweetener systems
6. Multiparticulate granules with controlled wetting

A successful product must preserve dose uniformity and extended release. Strong taste masking that delays wetting can create underexposure or an altered pharmacokinetic profile. A formulation that tastes acceptable in a small sensory screen may still fail because of sedimentation, syringe retention, or dose recovery.

Commercial positioning of a pediatric suspension

A pediatric mirabegron product can compete through:

• Lower reconstitution volume
• Smaller administration volume
• Longer in-use stability
• Better syringe dose recovery
• Improved flavor acceptance
• Reduced shaking requirements
• Compatibility with feeding tubes
• Unit-dose or ready-to-use packaging

These attributes can support a 505(b)(2) strategy or a differentiated international product, although the regulatory pathway depends on the extent of formulation and clinical differences from the reference product.

Which excipient technologies could support generic mirabegron?

The most practical generic strategy is a Q1/Q2-style formulation that uses the reference product’s functional excipient classes and matches critical material attributes. The objective is to minimize clinical and regulatory risk.

A second strategy is controlled excipient substitution. This can reduce cost or supply risk while preserving dissolution and pharmacokinetic behavior. High-priority substitutions include:

Reference function	Alternative development path	Main risk
Polyethylene oxide matrix	Hypromellose or polyethylene oxide from a second supplier	Release-rate drift
Conventional binder	Copovidone or hydroxypropyl cellulose	Granule density and compression changes
Conventional lubricant	Low-level sodium stearyl fumarate	Lubrication and dissolution differences
Standard coating	Polyvinyl alcohol or hypromellose film	Moisture ingress and appearance
Conventional filler	Mannitol, microcrystalline cellulose, or lactose	Tablet weight and compactibility
Surfactant system	Poloxamer or sodium lauryl sulfate	Wetting, tolerability, and dissolution

The third strategy is a reduced-size tablet. This may improve swallowability and packaging efficiency, but the developer must maintain the same dose, release profile, stability, and bioequivalence. High drug loading and stronger polymer matrices can reduce tablet dimensions, but they can also increase manufacturing variability.

What formulation patents protect mirabegron products?

Mirabegron protection has historically included active-compound, pharmaceutical-composition, dosage-form, and therapeutic-use claims. Formulation patents may cover controlled-release tablets, matrix systems, granules, suspension products, dosing regimens, or treatment of overactive bladder and neurogenic detrusor overactivity.

The relevant patent landscape has four layers:

Active pharmaceutical ingredient patents

These protect the mirabegron molecule or related chemical intermediates. Their expiration dates are jurisdiction-specific and may differ from later formulation or pediatric patents.

Extended-release formulation patents

These can cover polymer matrices, excipient ratios, dissolution profiles, tablet architecture, or manufacturing processes. Such patents create the greatest direct exposure for generic tablet developers because a product can be chemically identical to the reference drug while still encountering formulation claims.

Pediatric formulation patents

Granules for oral suspension may have separate protection directed to particle engineering, taste masking, reconstitution, stability, or administration. Pediatric products can therefore retain commercial barriers after adult tablet competition begins.

Method-of-use patents

Claims may cover use in overactive bladder, urgency urinary incontinence, urinary frequency, or neurogenic detrusor overactivity. Method-of-use claims can affect label strategy and Paragraph IV risk, although their practical enforcement depends on claim scope and the proposed generic label.

The FDA Orange Book should be used to identify listed U.S. patents, patent-use codes, and patent certifications for each approved dosage form.[3] The USPTO Patent Center and relevant district-court dockets should then be used to confirm prosecution history, terminal disclaimers, litigation, and ownership changes.[4]

When does mirabegron lose exclusivity and how will generic entry occur?

Mirabegron exclusivity is not determined by one date. The commercial transition depends on:

• New chemical entity exclusivity
• Listed compound patents
• Extended-release formulation patents
• Pediatric exclusivity
• Method-of-use patents
• Paragraph IV settlements
• Regulatory approval timing
• State substitution and payer contracting

An ANDA applicant can challenge listed patents through Paragraph IV certification. The patent holder may then file infringement litigation within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.[5]

Generic entry scenarios include:

Scenario	Market effect
First approved tablet ANDA with no litigation delay	Rapid price erosion and pharmacy substitution
Multiple ANDAs approved together	Steeper launch discounting
Authorized generic launch	Lower launch prices and reduced first-generic margin
Formulation patent litigation	Delayed entry or settlement-based launch
Pediatric-only competition	Limited impact on adult tablet revenue
Method-of-use carve-out	Potentially narrower label and reduced substitution
505(b)(2) suspension or chewable product	Differentiated pricing but higher clinical and regulatory burden

The most exposed asset is the adult 50 mg extended-release tablet because it is the dominant chronic dose and the simplest product for an ANDA developer to target. The pediatric suspension is more difficult to copy because it requires reconstitution, taste, dose uniformity, and device performance.

What is the FDA regulatory status of mirabegron formulations?

FDA approved Myrbetriq extended-release tablets in 2012 for overactive bladder. The approved adult indications include urinary urgency, urinary frequency, and urgency urinary incontinence associated with overactive bladder.[1]

FDA later approved Myrbetriq Granules for extended-release oral suspension for pediatric neurogenic detrusor overactivity.[2] This approval expanded the addressable population but also increased formulation complexity.

For excipient selection, the principal FDA issues are:

• Inclusion in the FDA Inactive Ingredient Database at the intended route and dose
• Grade and supplier qualification
• Residual solvents and elemental impurities
• Microbial control for reconstituted suspensions
• Extractables and leachables
• Nitrosamine and peroxide risk
• Dose uniformity after shaking and withdrawal
• Dissolution method discrimination
• Stability under temperature and humidity stress

An excipient with prior oral use is not automatically low risk. The relevant question is whether its concentration, route, dosage form, and patient population are supported by precedent and toxicology.

How strong is the mirabegron patent estate?

The estate is commercially meaningful because it combines a mature adult tablet with a newer pediatric delivery platform. Its strength is higher where claims are tied to measurable formulation characteristics, such as dissolution, particle size, reconstitution behavior, or polymer composition. Broad claims that depend only on general excipient classes are more vulnerable to design-around strategies.

Patent strength should be evaluated by:

1. Claim breadth across polymer classes
2. Dependence on exact excipient ratios
3. Presence of composition and process claims
4. Whether claims cover both 25 mg and 50 mg strengths
5. Whether pediatric granules have separate claims
6. Prosecution amendments and estoppel
7. Patent-term adjustment and terminal disclaimers
8. Prior-art disclosures involving beta-3 agonist formulations
9. Ownership and licensing records
10. Litigation outcomes and settlement restrictions

A generic developer should prioritize non-infringing design-around work before finalizing the matrix polymer and pediatric suspension architecture.

What commercial opportunities exist for excipient suppliers and formulation companies?

The strongest opportunities are concentrated in five areas.

Controlled-release polymer supply

Suppliers can differentiate through low-peroxide polyethylene oxide, high-consistency hypromellose, and technical support for scale-up. Documentation packages that support ANDA chemistry, manufacturing, and controls submissions have direct value.

Pediatric taste-masked granules

Contract development organizations can offer a complete platform covering coated particles, suspension rheology, flavor screening, syringe recovery, and in-use stability.

Bioequivalence-enabling formulation services

Companies with dissolution modeling, physiologically based pharmacokinetic tools, and modified-release development capability can reduce formulation iteration for generic applicants.

Excipient substitution and dual sourcing

A qualified second source for the release-controlling polymer can protect supply continuity. This is commercially attractive because polymer variability can materially affect dissolution and batch release.

Differentiated dosage forms

Potential products include smaller tablets, sprinkle-compatible multiparticulates, oral suspensions, feeding-tube-compatible presentations, and combination products with other overactive bladder therapies. Each option carries greater regulatory risk than a conventional ANDA tablet but may support longer commercial protection.

How does mirabegron compare with competing overactive bladder drugs?

Product	Active ingredient	Dosage-form profile	Competitive implication
Myrbetriq	Mirabegron	Extended-release tablet; pediatric granules	Strong formulation and pediatric platform
Gemtesa	Vibegron	Once-daily tablet	Direct beta-3 agonist competitor
Detrol LA	Tolterodine	Extended-release capsule	Generic antimuscarinic pressure
Vesicare	Solifenacin	Tablet and suspension in some markets	Established generic competition
Enablex	Darifenacin	Extended-release tablet	Antimuscarinic alternative
Oxytrol and related products	Oxybutynin	Transdermal or oral products	Delivery-system differentiation

Mirabegron avoids the anticholinergic burden associated with antimuscarinics, but it carries its own safety and labeling considerations, including blood-pressure monitoring. Vibegron competes directly on mechanism and once-daily convenience. Excipient differentiation alone is unlikely to offset a major price difference unless it improves pediatric use, adherence, administration, or supply reliability.

What revenue exposure does generic mirabegron create?

Astellas reported Myrbetriq sales of approximately ¥196 billion in fiscal 2023, making the product a material revenue contributor.[6] The largest exposure is the U.S. adult tablet market, where generic substitution can rapidly reduce net pricing after one or more ANDA approvals.

Revenue erosion will depend on:

• Number of approved ANDAs
• Timing of the first generic launch
• Authorized-generic strategy
• Managed-care formulary placement
• Patent settlement terms
• Relative uptake of vibegron
• Pediatric product protection
• International patent and reimbursement timing

The pediatric granule market is smaller but may have higher switching friction because prescribers and caregivers value dosing reliability, taste, and administration devices. That makes excipient and packaging performance commercially relevant even after adult tablet competition begins.

Key Takeaways

• Mirabegron’s central formulation challenge is controlled release of a poorly water-soluble active ingredient.
• Polyethylene oxide and hypromellose are the principal polymer platforms for extended-release development.
• Low-peroxide polymer supply, excipient dual sourcing, and bioequivalence-enabling formulation services are attractive B2B opportunities.
• Pediatric granules for oral suspension create a separate opportunity in taste masking, suspension stability, syringe recovery, and reconstitution performance.
• Adult 50 mg extended-release tablets face the highest generic-entry risk.
• Formulation, pediatric, process, and method-of-use patents should be analyzed separately from compound patents.
• The FDA Orange Book, patent prosecution records, and litigation dockets are required to determine current Paragraph IV exposure.
• Astellas’ large Myrbetriq revenue base creates meaningful commercial value for both generic challengers and excipient suppliers.
• A smaller tablet, pediatric suspension, or administration-compatible product could support differentiation, but each path increases regulatory complexity.
• Excipient selection should be driven by dissolution robustness, bioequivalence, supply security, and patent design-around potential.

FAQs

Can mirabegron be formulated as an immediate-release tablet?

Yes, but an immediate-release product would not automatically replicate the approved once-daily extended-release profile. A modified-release formulation is the commercially relevant target for the primary branded product.

Which excipient is most likely to determine mirabegron bioequivalence?

The release-controlling polymer is usually the highest-impact excipient because its molecular weight, concentration, hydration, and processing history can change dissolution and exposure.

Is pediatric mirabegron more difficult to genericize than adult tablets?

Yes. Pediatric products require taste masking, reconstitution control, weight-based dosing, suspension uniformity, in-use stability, and reliable oral-syringe delivery in addition to pharmacokinetic equivalence.

Can a generic mirabegron developer use a different polymer from the reference product?

Potentially. The developer must demonstrate comparable release and bioequivalence while assessing formulation-patent claims. A different polymer can reduce infringement risk but may increase development and regulatory risk.

Are excipient suppliers exposed to mirabegron patent litigation?

Usually, the principal litigation risk falls on the drug-product applicant. Excipient suppliers can still face commercial exposure if their materials are identified in formulation claims, process claims, or technical documents used to support an allegedly infringing product.

References

1. U.S. Food and Drug Administration. (2023). Myrbetriq (mirabegron) prescribing information.
2. U.S. Food and Drug Administration. (2021). Myrbetriq Granules (mirabegron) for extended-release oral suspension prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. United States Patent and Trademark Office. (2024). Patent Center.
5. U.S. Food and Drug Administration. (2017). ANDAs for certain highly purified synthetic peptides and abbreviated new drug application submissions.
6. Astellas Pharma Inc. (2024). Annual report and financial results for fiscal year ended March 31, 2024.